Eli Lilly Japan K.K. and Sumitomo Pharma Co., Ltd. announced that the domestic sales collaboration for Glucagon-like peptide-1 (GLP-1) receptor agonist "Trulicity® Subcutaneous Injection 0.75 mg Ateos®, which is used for the treatment of type 2 diabetes, will conclude upon the expiration of the contract period on December 31, 2022. Eli Lilly Japan and Sumitomo Pharma signed the domestic sales collaboration agreement for Trulicity in July 2015. Based on this agreement, Sumitomo Pharma has taken responsibility for sales/distribution of Trulicity, while Eli Lilly Japan retains a manufacturing/marketing license, and both companies have been providing information to medical professionals.

With the expiration of the term of this agreement, from January 2023, Eli Lilly Japan will be responsible for sales/distribution and will provide information. Sumitomo Pharma will end its sales/distribution and information provision activities on December 31, 2022. Eli Lilly Japan and Sumitomo Pharma will work closely together to facilitate transfer of Trulicity so as to ensure continued stable product supply and adequate information services.